ScreenerHero

GPCR Structure Therapeutics Inc.

NAS · US · Healthcare · Biotechnology · structuretx.com
26.68USD-2.88%Mkt Cap: 1.90B $P/E: —

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap1.90B USD
Enterprise Value622.45M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-141.20M USD
Revenue/Share—
Last Price26.68 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees281
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-13.00
PEG—
EV/EBITDA-2.34
EV/Revenue—
P/S—
P/B1.44
EPS (TTM)-3.02
EPS (Forward)-2.11
52W Range
24.543% of range94.90
52W High94.90 USD
52W Low24.54 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-9.31%
ROA-8.91%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-222.20M USD
CapEx (TTM)3.61M USD
FCF Margin—
FCF Yield-6.26%
Net Debt-1.34B USD
Net Debt/EBITDA5.03
Balance Sheet
Debt/Equity0.00
Current Ratio20.75
Quick Ratio20.31
Book Value/Sh19.02 USD
Cash/Share18.83 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)105.78 USD
Upside (mean)+296.5%
Target Range70.00 USD – 145.00 USD
70.00+296.5% to mean145.00
# Analysts15
Ownership
Shares Out.71.31M
Float55.46M
Insiders3.11%
Institutions97.70%
Short Interest
Short Ratio6.6d
Short % Float12.68%
Short % Out.9.26%
Shares Short6.61M
Short (prev mo.)6.08M
Technical
SMA 5044.28 (-39.7%)
SMA 20053.35 (-50.0%)
Beta-1.37
S&P 52W Chg16.45%
Avg Vol (30d)1.11M
Avg Vol (10d)1.71M
Technical Indicators
RSI (14)16.3
MACD-4.9511
MACD Signal-4.3629
MACD Hist.-0.5882
BB Upper44.02 USD
BB Middle34.56 USD
BB Lower25.10 USD
BB Width54.75%
ATR (14)2.219 USD
Vol Ratio (20d)0.79x